Yesterday, Sara Hallum Søndergaard and Cathrine Tipsmark from our Danish office attended the Danish Society for Pharmacoepidemiology 2025 Annual Meeting, exploring how academic–industry partnerships can advance reliable RWE.
📊 Key takeaways:
➡️ Register-based RCTs enabling cost-efficient, large-scale trials
➡️ Case-crossover designs for cumulative drug effects
➡️ Growing trust in RWE among European payers
It was energising to connect with both industry and academic colleagues on how registry-based research can support the full drug life cycle.
💬 How are you seeing public–private partnerships shape RWE generation?
